Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans specific to the patient.
Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.
Testing for a specific cancer protein markers in lung cancer patients' blood helps find those more likely to respond to Tarceva, a drug sold by Roche.
CBSA's May BioBreakfast allowed two of Colorado's 2009 Bioscience success stories to share their stories. First up was Biodesix, in the diagnostic space.
Presenting current issues with lung cancer tissue testing, followed by a discussion of Veristrat, Biodesix proteomic serum test for predicted tumor response
The number of studies at this year's European Lung Conference suggest notable progress in personalized medicine as well as the understanding of lung cancer.
A new blood test could improve the use of a popular lung cancer drug called erlotinib by allowing doctors to select which patients will react positively.
One data point doesn't tell you very much in most cases. This principle guides Biodesix's approach to developing diagnostics.